Patents Assigned to Cleveland Clinic Foundation
  • Patent number: 10799145
    Abstract: System and methods are disclosed to facilitate intra-operative procedures and planning. A method can include storing tracking data in memory, the tracking data being generated by a tracking system to represent a location of an object in a tracking coordinate system of the tracking system. The method can also include storing a patient-specific implicit model in memory, the patient-specific implicit model being generated based on image data acquired for the patient to define geometry of an anatomical structure of the patient. The method can also include registering the tracking data and the patient-specific implicit model in a common three-dimensional coordinate system. The method can also include generating an output visualization representing a location of the object relative to the geometry of the anatomical structure of the patient in the common coordinate system.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 13, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Karl West, Vikash Goel, James Foster
  • Patent number: 10799360
    Abstract: A system for treating regurgitation of blood through a diseased heart valve having at least two leaflets can include an implantable, lollipop-shaped device and an adjustment mechanism. The device can have a proximal end portion, a distal end portion, and an intermediate portion extending therebetween. The intermediate portion can include an expandable occluding member having a selectively adjustable diameter and a biocompatible layer attached to at least a portion thereof. The distal end portion can include an anchoring member. The adjustment member can include a distal connecting end that is operatively connected to the proximal end portion of the device. Operation of the adjustment member, after implantation of the device, can cause the diameter of the occluding member to change so that at least one of the heart leaflet coapts with a portion of the occluding member to mitigate or prevent regurgitation of blood through the diseased heart valve.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: October 13, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Samir Kapadia
  • Patent number: 10792393
    Abstract: A biocompatible tissue graft is provided. The tissue graft includes an extracellular matrix patch and a means for reinforcing the patch.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 6, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Kathleen A. Derwin, Amit Aurora, Joseph P. Iannotti, Jesse A. McCarron
  • Patent number: 10786479
    Abstract: The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: September 29, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Stanley Leon Hazen, Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, David Thomas Stanton, Thomas Alfred Inglin, Michael Reilly, Angela Jane Deutsch, Jodie Michele Reed, David Blair Cody
  • Patent number: 10786640
    Abstract: One aspect of the present disclosure relates to a reversible airway device. The reversible airway device (10) can include: a supra-glottic airway support (12) comprising a multi-lumen tubular guide (14) and an optional sealing member (16); an endotracheal tube (26); and at least one seal (42). The multi-lumen tubular guide has a distal end portion (18), a proximal end portion (22), a first passageway (20) extending between the distal and proximal end portions, and a second passageway (24) that is non-concentric with the first passageway and also extends between the distal and proximal end portions. The at least one seal is disposed within the first passageway, the second passageway, or both, so as to occlude the flow of a gas through the first passageway and/or the second passageway. The endotracheal tube can be inserted into the first or second passageway and can traverse the seal.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: September 29, 2020
    Assignees: PARKER-HANNIFIN CORPORATION, THE CLEVELAND CLINIC FOUNDATION
    Inventors: Rafi Avitsian, Andrew Zura, Gino Banco, Sean Lee
  • Patent number: 10779930
    Abstract: An endoluminal prosthesis may include a tubular main graft body including a sidewall and proximal and distal ends. A first stent may be positioned near the proximal end of the main graft body. A second stent may be positioned adjacent to and distal of the first stent. An opening in the sidewall may be positioned longitudinally between a peak of the first stent and a valley of the second stent. A tubular branch may be disposed in the opening. The branch may include first and second end openings. The branch may be flexibly orientable between a retrograde configuration in which the first end opening is oriented toward the distal end and the second end opening is oriented toward the proximal end and an antegrade configuration in which the first end opening is oriented toward the proximal end and the second end opening is oriented toward the distal end.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 22, 2020
    Assignees: The Cleveland Clinic Foundation, Cook Medical Technologies LLC
    Inventors: Blayne A. Roeder, Roy K. Greenberg, Jarin Kratzberg, Matthew S. Huser
  • Patent number: 10780072
    Abstract: The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: September 22, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Stanley Leon Hazen, Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, David Thomas Stanton, Thomas Alfred Inglin, Michael Reilly, Angela Jane Deutsch, Jodie Michele Reed, David Blair Cody
  • Patent number: 10779731
    Abstract: A patient management system includes a patient unit that obtains results data from a patient device and provides for two-way communication between the patient unit and a remote database. The patient unit can communicate with the remote database to obtain encounter instruction data for a given encounter as well as to send response data for the given encounter. A back office system can also access the database to retrieve the patient data for one or more patient users. The back office system can further add or modify encounter instruction data for use during a next encounter at the patient unit. The back office system can also set a dosage for the patient that can be stored in the remote database and retrieved by the patient unit as part of the given encounter. The back office system may also employ a rules engine that can be programmed according to an established protocol and can automatically generate encounter instructions and dosage information for one or more patient.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: September 22, 2020
    Assignees: THE CLEVELAND CLINIC FOUNDATION, ZTECH, INC.
    Inventors: Alan Chmiel, Heather Gornik, John R. Bartholomew, Carlos Grodsinsky, Jonathan Schaffer
  • Patent number: 10758387
    Abstract: A pre-loaded delivery device that facilitates accurate placement of a stent graft assembly in the aorta is disclosed. A stent graft is carried on the delivery device and held in a pre-deployment configuration by a sheath. A split in the sheath facilitates the pre-cannulation of one or more branch arteries extending from the aorta before the stent graft is fully released in the aorta. The stent graft comprises a tubular body having at least one scalloped fenestration formed in one end of the graft material and at least one fenestration formed in the graft material of the main tubular body. A helical internal side branch extends from the fenestration within the lumen of the main tubular body. The helical side branch is configured to curve at least partially around the scalloped fenestration. The assembly further comprises a connection stent graft extending from the fenestration into a branch vessel.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: September 1, 2020
    Assignees: Cook Medical Technologies LLC, The Cleveland Clinic Foundation
    Inventors: Blayne A. Roeder, Roy K. Greenberg, Stephan Haulon
  • Patent number: 10758644
    Abstract: A biocompatible tissue graft is provided. The tissue graft includes an extracellular matrix patch and a means for reinforcing the patch.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: September 1, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Kathleen Derwin, Amit Aurora, Joseph P. Iannotti, Jesse A. McCarron
  • Patent number: 10751301
    Abstract: A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising a compound set forth in Formula (I):
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 25, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Jose Carlos Garcia-Garcia, George Franklin Gerberick, Michael Reilly, Stanley Leon Hazen, Xiaodong Gu
  • Patent number: 10741287
    Abstract: In an example embodiment, this disclosure provides a non-transitive computer-readable medium on which are stored instructions executable by a processor, the instructions which, when executed by the processor, cause the processor to perform a method. The method includes computing, based on test performance data of a user, at least one of a performance variable characterizing cognitive functioning and a performance variable characterizing neuromotor functioning. For each of the at least one performance variable, a respective score can be computed based on the respective performance variable and based on a set of performance metrics. The method can also include outputting, via an output device, the at least one computed score.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 11, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jay L. Alberts, Cameron McIntyre
  • Patent number: 10729659
    Abstract: Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: August 4, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Vinod Labhasetwar, Sivakumar Vijayaraghavalu
  • Patent number: 10730016
    Abstract: The present invention relates to ultrafiltration. In particular, the present invention provides nanoporous membranes having pores for generating in vitro and in vivo ultrafiltrate, devices and bioartificial organs utilizing such nanoporous membranes, and related methods (e.g., diagnostic methods, research methods, drug screening). The present invention further provides nanoporous membranes configured to avoid protein fouling with, for example, a polyethylene glycol surface coating.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 4, 2020
    Assignees: The Regents of the University of Michigan, The Cleveland Clinic Foundation
    Inventors: William H. Fissell, Shuvo Roy, Aaron Fleischman, Kenneth G. Goldman
  • Patent number: 10722342
    Abstract: A branched and fenestrated prosthesis may include a main tubular graft body including a proximal end opening, a distal end opening, a lumen, and a sidewall. A branch may extend from the sidewall and may include a first end opening, a second end opening, and a lumen. A fenestration may be disposed in the sidewall and positioned distal of the second end opening of the branch. The branched and fenestrated prosthesis may include a plurality of branches and a plurality of fenestrations.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: July 28, 2020
    Assignees: The Cleveland Clinic Foundation, Cook Medical Technologies LLC
    Inventors: Roy K. Greenberg, Karl J. West, Timothy A. Resch, Blayne A. Roeder
  • Patent number: 10695122
    Abstract: This disclosure relates to forming a lesion in a patient's neurological tissue without requiring general anesthesia. The lesion can be either temporary or permanent. In either case, the lesion can be created by a steerable probe that includes a steerable guide, a laser device, and at least one electrode. The steerable guide steers the probe to a target location in the subject's neurological tissue. When the probe reaches the target location, the laser can create the lesion. The at least one electrode can detect a progressive vanishing of neural activity from the portion of the neurological tissue due to the lesion.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 30, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jorge Gonzalez-Martinez, Imad Najm, John T. Gale, Karl West
  • Patent number: 10675448
    Abstract: A controller (10) for manually controlling a guidewire (50) includes a housing (100) including a passage (112) for receiving the guidewire. A gripper (140) is actuatable to grasp the guidewire (50) in the passage (112). A cap (200) is connected to the housing (100). The cap (200) is rotatable relative to the housing (100) to actuate the gripper (140). The housing (100) includes an element (160) for maintaining the cap (200) in a receiving position. The cap (200) when in the receiving position places the controller (10) in a condition for receiving the guidewire (50).
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: June 9, 2020
    Assignees: PARKER-HANNIFIN CORPORATION, WINDCREST LLC, THE CLEVELAND CLINIC FOUNDATION
    Inventors: David R. Whittaker, Ryan S. Klatte, Shawn D. Ellis, Jason T. Mikulski
  • Patent number: 10675425
    Abstract: A reversible airway device can include a tubular guide, a laryngeal mask, and an endotracheal tube. The tubular guide can have a distal end portion, a proximal end portion, and a first passageway extending between the distal and proximal end portions. The tubular guide can further include a first longitudinal seam. The laryngeal mask can be attached to the distal end portion of the tubular guide. The laryngeal mask can include an opening in fluid communication with the first passageway. The laryngeal mask can further include a second longitudinal seam. The endotracheal tube can be slidably disposed within the first passageway and have a second passageway. The first and second longitudinal seams can be adapted to permit ingress and egress of the tubular guide from the airway without detaching the endotracheal tube from a ventilation source.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 9, 2020
    Assignees: THE CLEVELAND CLINIC FOUNDATION, PARKER HANNIFIN CORPORATION
    Inventors: Rafi Avitsian, Andrew Zura, Ricardo Gonzalez, Michael Collinson, Gino Banco, Marijan Matakovic
  • Patent number: 10675256
    Abstract: A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising a compound set forth in Formula (I):
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: June 9, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, Stanley Leon Hazen, Xiaodong Gu
  • Patent number: 10675467
    Abstract: One aspect of the present disclosure relates to a system for treating obstructive sleep apnea in a subject. The system can include a power source and a neuromuscular stimulator in electrical communications with the power source. The neuromuscular stimulator can include a controller and at least one electrode. The controller can be configured to receive certain power and stimulation parameters associated with a therapy signal from the power source. The at least one electrode can be configured to deliver the therapy signal to a target tissue associated with control of a posterior base of the tongue of the subject.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 9, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Francis A. Papay